Focused On-demand Library for Disrupted in schizophrenia 1 protein

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q9NRI5

UPID:
DISC1_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9NRI5; A6NLH2; C4P091; C4P095; C4P0A1; C4P0A3; C4P0B3; C4P0B6; C4P0C1; C9J6D0; O75045; Q5VT44; Q5VT45; Q8IXJ0; Q8IXJ1; Q9BX19; Q9NRI3; Q9NRI4

BACKGROUND:
Disrupted in Schizophrenia 1 protein is integral to the regulation of embryonic and adult neurogenesis, impacting neural progenitor proliferation and hippocampal development. It positively regulates Wnt-mediated neural progenitor proliferation and plays a significant role in the AKT-mTOR signaling pathway, affecting neuron positioning and synapse formation. Its interaction with CCDC88A inhibits AKT-mTOR signaling, highlighting its regulatory capacity in neuronal development.

THERAPEUTIC SIGNIFICANCE:
The connection of Disrupted in Schizophrenia 1 protein with schizophrenia underscores its therapeutic potential. By elucidating its regulatory mechanisms in neurogenesis and neural signaling pathways, novel therapeutic approaches for schizophrenia and related neurological conditions could be developed, leveraging its critical role in brain development and function.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 483 of 8789